The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway

Molecular and Cellular Biochemistry

Volumn 380, Issue 1-2, 2013, Pages 249-257

  Wu, Xiaojin ^a   Mi, Yanyan ^b   Yang, Hui ^a   Hu, Ankang ^b   Zhang, Qingguo ^a   Shang, Chunli ^a  

^a First People's Hospital of Xuzhou   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

HMGB 1; Inflammation; JNK; Normal human bronchial epithelial cells; NSCLC; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 8; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRONCHUS MUCOSA; DOSE RESPONSE; HUMAN; HUMAN CELL; INFLAMMATION; LUNG NON SMALL CELL CANCER; PRECANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTHRACENES; BLOTTING, WESTERN; BRONCHI; CELL LINE; CHEMOKINE CCL2; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-8; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICROSCOPY, FLUORESCENCE; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879795105     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1680-0     Document Type: Article

References (32)

1. Chunhacha P, Chanvorachote P (2012) Roles of caveolin-1 on anoikis resistance in non small cell lung cancer. Int J Physiol Pathophysiol Pharmacol 4:149-155
2. Emmendoerffer A, Hecht M, Boeker T, Mueller M, Heinrich U (2000) Role of inflammation in chemical-induced lung cancer. Toxicol Lett 112-113:185-191
3. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R (2012) Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J Immuno 189:4674-4683
4. Tao Y, Gu YJ, Cao ZH, Bian XJ, Lan T, Sang JR, Jiang L, Wang Y, Qian H, Chen YC (2012) Endogenous cGMP-dependent protein kinase reverses EGF-induced MAPK/ERK signal transduction through phosphorylation of VASP at Ser239. Oncol Lett 4:1104-1108
5. Houghton AM (2012) Endogenous modifiers of cigarette smoke exposure within the lung. Proc Am Thorac Soc 9:66-68
6. Smolarczyk R, Cichoń T, Jarosz M, Szala S (2012) HMGB1-its role in tumor progression and anticancer therapy. Postepy Hig Med Dosw (Online) 66:913-920
7. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H, Kuniyasu H (2012) High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer. doi: 10.1016/j.ejca.2012.09.016
8. Naglova H, Bucova M (2012) HMGB1 and its physiological and pathological roles. Bratisl Lek Listy 113:163-171
9. Nogueira-Machado JA, de Oliveira Volpe CM (2012) HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov 6:201-209
10. Logsdon CD, Fuentes MK, Huang EH, Arumugam T (2007) RAGE and RAGE ligands in cancer. Curr Mol Med 7:777-789
11. Khan A, Vaibhav K, Javed H, Khan MM, Tabassum R, Ahmed ME, Srivastava P, Khuwaja G, Islam F, Siddiqui MS, Shafi MM, Islam F (2012) Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol Cell Biochem 369:55-65
12. Xu Y, Feng L, Wang S, Zhu Q, Lin J, Lou C, Xiang P, He B, Zheng Z, Tang D, Zuo G (2011) Phytoestrogen calycosin-7-O-β-D-glucopyranoside ameliorates advanced glycation end products-induced HUVEC damage. J Cell Biochem 112:2953-2965
13. Zhang Y, Dong J, He P, Li W, Zhang Q, Li N, Sun T (2012) Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis. Inflammation 35:377-387
14. Mantell LL, Parrish WR, Ulloa L (2006) Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25:4-11
15. Ohmori H, Luo Y, Kuniyasu H (2011) Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets 15:183-193
16. Nogueira-Machado JA, de Oliveira Volpe CM (2012) HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov 6:201-209
17. Bezerra FS, Valença SS, Pires KM, Lanzetti M, Pimenta WA, Schmidt AC, Porto LC, Zin WA (2011) Long-term exposure to cigarette smoke impairs lung function and increases HMGB-1 expression in mice. Respir Physiol Neurobiol 177:120-126
18. Choi J, Lee MK, Oh KH, Kim YS, Choi HY, Baek SK, Jung KY, Woo JS, Lee SH, Kwon SY (2011) Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori 97:196-202
19. Feng L, Zhu M, Zhang M, Jia X, Cheng X, Ding S, Zhu Q (2012) Amelioration of compound 4, 4′-diphenylmethane-bis(methyl)carbamate on high mobility group box1-mediated inflammation and oxidant stress responses in human umbilical vein endothelial cells via RAGE/ERK1/2/NF-κB pathway. Int Immunopharmacol 15:206-216. doi: 10.1016/j.intimp.2012.11.015
20. Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, Negi MP, Srivastava AN (2010) Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology 15:349-356
21. Tertil M, Jozkowicz A, Dulak J (2010) Oxidative stress in tumor angiogenesis-therapeutic targets. Curr Pharm Des 16:3877-3894
22. Lau ST, Lin ZX, Leung PS (2010) Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br J Cancer 102:583-593
23. Dejean E, Foisseau M, Lagarrigue F, Lamant L, Prade N, Marfak A, Delsol G, Giuriato S, Gaits-Iacovoni F, Meggetto F (2012) ALK + ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation. Blood 119:4698-4707
24. Sabapathy K (2012) Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci 106:145-169
25. Könczöl M, Ebeling S, Goldenberg E, Treude F, Gminski R, Gieré R, Grobéty B, Rothen-Rutishauser B, Merfort I, Mersch-Sundermann V (2011) Cytotoxicity and genotoxicity of size-fractionated iron oxide (magnetite) in A549 human lung epithelial cells: role of ROS, JNK, and NF-κB. Chem Res Toxicol 24:1460-1475
26. Xu H, Yao Y, Su Z, Yang Y, Kao R, Martin CM, Rui T (2011) Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK. Am J Physiol Heart Circ Physiol 300:H913-H921
27. Warmka JK, Solberg EL, Zeliadt NA, Srinivasan B, Charlson AT, Xing C, Wattenberg EV (2012) Inhibition of mitogen activated protein kinases increases the sensitivity of A549 lung cancer cells to the cytotoxicity induced by a kava chalcone analog. Biochem Biophys Res Commun 424:488-492
28. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q (2011) Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 58:482-490
29. Yang L, Shi GL, Song CX, Xu SF (2010) Relationship between genetic polymorphism of MCP-1 and non-small-cell lung cancer in the Han nationality of North China. Genet Mol Res 9:765-771
30. Zhang XW, Qin X, Qin CY, Yin YL, Chen Y, Zhu HL (2013) Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance. Cancer Immunol Immunother 62:563-570
31. Nakasone Y, Fujimoto M, Matsushita T, Hamaguchi Y, Huu DL, Yanaba M, Sato S, Takehara K, Hasegawa M (2012) Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. Am J Pathol 180:365-374
32. Zhou JG, Dong JY, Zhang LH, Wang J (2011) Expression of high mobility group box chromosomal protein 1 in mice with lupus nephritis. Zhejiang Da Xue Xue Bao Yi Xue Ban 40:200-206